The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InKalVista Pharmaceuticals announced that its drug EKTERLY (sebetralstat) has been included in the newly published international guidelines as a first-line treatment for Hereditary Angioedema (HAE) attacks. The recommendation specifically covers the acute treatment of HAE attacks in adolescents aged 12 years and older, strengthening the drug's market position. This decision by the international committee is supported by robust, high-quality evidence from clinical trial data demonstrating the drug's efficacy and safety. Being recognized as a first-line therapy marks a significant commercial milestone that is expected to drive widespread adoption and improve insurance coverage. Analysts view this development as a positive driver for KalVista's long-term revenue potential within the biotechnology sector. Shares of KalVista Pharmaceuticals are currently traded on the Nasdaq under the ticker KALV.